Scribe Therapeutics (SCTX) vs Vanda Pharmaceuticals (VNDA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Scribe Therapeutics is the larger company by market cap ($389.2 million vs $276.0 million), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SCTX | VNDA |
|---|---|---|
| Share price | $20.56 | $4.57 |
| Market cap | $389.24M | $276.01M |
| 1-day change | +6.94% | +0.77% |
| YTD return | — | -48.64% |
| 1-year return | — | -17.03% |
| 5-year return | — | -75.39% |
| Forward P/E | — | 22.83 |
| EPS (TTM) | $-3.84 | $-4.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $39.60 | $9.94 |
| 52-week low | $13.50 | $4.27 |
| Distance from 52-week high | -48.08% | -54.07% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +177.24% | +157.39% |
| Average volume | 357.40K | 974.13K |
| Shares outstanding | 18.93M | 60.46M |
| Employees | 82 | 533 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Scribe Therapeutics
SCTX stock →Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 82 employees
About Vanda Pharmaceuticals
VNDA stock →Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion.
Health Care · Biotechnology: Pharmaceutical Preparations · 533 employees
SCTX vs VNDA FAQ
Which is bigger, Scribe Therapeutics or Vanda Pharmaceuticals?
Scribe Therapeutics (SCTX) is larger, with a market capitalization of $389.24M compared with $276.01M for Vanda Pharmaceuticals (VNDA).
Are Scribe Therapeutics and Vanda Pharmaceuticals in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Scribe Therapeutics and Biotechnology: Pharmaceutical Preparations for Vanda Pharmaceuticals.